FIRST CASE OF EXCLUSIVELY DOPAMINE-SECRETING PARAGANGLIOMA IN MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A (MEN2A)
DOI:
https://doi.org/10.15605/jafes.037.S2.16Keywords:
multiple endocrine neoplasia, MEN2A, paragangliomaAbstract
INTRODUCTION
Pheochromocytomas in MEN2A are usually intra-adrenal, though they may uncommonly manifest as paragangliomas. Predominantly or exclusively dopamine-secreting pheochromocytomas and paragangliomas (PPGL) are rare with only 33 cases reported in the literature. We report the first case of exclusively dopamine paraganglioma in the context of MEN2A.
CASE
A 72-year-old male was diagnosed with MEN2A following a family screening in 1996. Genetic analysis revealed a mutation in codon 634 of the RET proto-oncogene (C634Y). He underwent total thyroidectomy for medullary thyroid carcinoma in 1996 and total parathyroidectomy for primary hyperparathyroidism in 1997. His yearly 24-hour urinary catecholamines had been within the normal ranges. However, in August 2019, his urinary dopamine was raised to 1033 μg/day (Normal range: 64.0-400). Urinary adrenaline and noradrenaline were not elevated. Repeated 24-hour urinary metanephrines in August 2020 yielded an elevated 3-methoxytyramine level of 21.8 μmol/day (Normal range: 0.10-1.79). Urinary metanephrines and normetanephrines remained within normal ranges. He has hypertension which was well-controlled on two agents. He is, otherwise, asymptomatic with no paroxysmal attacks of headaches, sweating or palpitations. Iodine-131 meta-iodobenzylguanidine (I-131 MIBG) imaging revealed an avid lesion in the mediastinum with no tracer uptake at the adrenal glands. The patient declined further interventions.
CONCLUSION
Despite the rarity of exclusively dopamine-secreting PPGL, the case highlights the importance of measuring urinary or plasma dopamine in MEN2A. Dopamine-secreting PPGL typically lacks the classical presentation of paroxysmal attacks and is often extra-adrenal. The patient was diagnosed with PPGL at 70 years of age. As the prevalence of PPGL in MEN2A increases with age, there is no age cut-off to stop screening.
Downloads
References
*
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Chiew Ken Seng, Velaiutham Shanty, Khaw Chong Hui

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The full license text is available at: http://creativecommons.org/licenses/by-nc/3.0/legalcode.
To request permission to translate, reproduce, download, or use articles or images for commercial reuse or business purposes from the Journal of the ASEAN Federation of Endocrine Societies (JAFES), kindly complete the Permission Request for Use of Copyrighted Material Form and email jafes@asia.com or jafes.editor@gmail.com.
A written agreement will be issued to the requester once permission has been granted.





